Glandokort

1. Overview

Glandokort (Cytomax A-17) is a natural peptide bioregulator complex extracted from the adrenal glands of young animals (calves and pigs under 12 months of age), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology [1][2]. Each capsule contains a complex of low-molecular-weight peptides with molecular weights up to 5,000 Da that are proposed to selectively target adrenal cortex tissue, restoring hormonal production and metabolic function.

Within the Khavinson bioregulator system, Glandokort addresses the adrenal glands -- the endocrine organs responsible for producing cortisol (stress response and metabolism), aldosterone (blood pressure and electrolyte balance), and androgenic precursors including DHEA and 17-ketosteroids (sex hormone precursors and anabolic activity). Age-related decline in adrenal function, compounded by chronic stress, is proposed to contribute to fatigue, immune dysfunction, metabolic disturbances, and accelerated aging [1][4].

Unlike some other Khavinson bioregulators that have defined synthetic analogs (Epithalon for pineal, Cortagen for brain cortex, Thymogen for thymus), no publicly identified single synthetic peptide has been derived from the adrenal gland extract. The sequence AEDLA (Ala-Glu-Asp-Leu-Ala) has been associated with Glandokort in some sources, but this association lacks the peer-reviewed documentation that supports the AEDG-Epithalon or AEDP-Cortagen connections.

The clinical evidence for Glandokort consists of a single open-label study conducted at Khavinson's institution involving 36 patients with chronic adrenal cortex insufficiency, which showed restoration of adrenal hormonal function. No independent replication exists.

Type

Polypeptide complex (adrenal gland extract), not a single peptide

Source

Adrenal glands of calves and pigs under 12 months of age

Molecular Weight Range

Up to 5,000 Da (low-molecular-weight peptide fraction)

Cytomax Designation

A-17 (adrenal gland bioregulator)

Target Tissue

Adrenal cortex (zona reticularis, zona glomerulosa, zona fasciculata)

Hormones Affected

Cortisol, aldosterone, 17-ketosteroids (DHEA/androgenic precursors), insulin

Route

Oral (capsules); sublingual (Lingual Glandokort)

Developer

Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology

Regulatory Status

Available as dietary supplement in Russia; not approved by FDA, EMA, or any Western regulatory agency

2. Mechanism of Action

Glandokort's mechanism of action is understood through the general framework of Khavinson's peptide bioregulation theory, applied to adrenal cortex tissue. No adrenal-specific molecular mechanism studies (comparable to the Cortagen microarray or Epithalon telomerase studies) have been published.

Tissue-Specific Gene Expression Regulation

Following the core principle of peptide bioregulation, the short peptides in Glandokort are proposed to selectively interact with DNA in adrenal cortex cells, binding to specific promoter regions and modulating transcription of genes involved in steroidogenesis (the biochemical pathway of cortisol, aldosterone, and androgen synthesis) [1][5][6].

The proposed mechanism involves:

1. Cell penetration: Ultra-short peptides (2-4 amino acids) cross cell membranes without requiring receptor-mediated endocytosis or active transport [6]
2. Nuclear translocation: Peptides enter the cell nucleus and interact directly with chromosomal DNA [6]
3. Promoter binding: Peptides bind to specific DNA sequences in the promoter regions of steroidogenic genes
4. Transcriptional activation: Gene expression is upregulated, restoring production of hormones that have declined due to aging, stress, or disease

Adrenal Cortex Zone Restoration

The clinical study data suggests that Glandokort specifically restores the metabolic activity of the reticular zone (zona reticularis) of the adrenal cortex. This zone is responsible for producing androgenic precursors (DHEA, DHEA-S, androstenedione) and is the zone most susceptible to age-related atrophy. The restoration manifests as increased production of 17-ketosteroids, the metabolic products of androgenic steroids [4].

Hormonal Normalization

Rather than stimulating hormone production to supraphysiological levels, Glandokort is proposed to normalize hormonal output -- increasing deficient production and potentially stabilizing excessive production. This self-regulating property is a central tenet of the bioregulator theory and distinguishes it from exogenous hormone replacement, which can suppress endogenous production through negative feedback [1][2].

Epigenetic Mechanisms

By analogy with the documented epigenetic effects of other Khavinson peptides (Cortagen's chromatin remodeling [7], Epithalon's histone binding [14]), Glandokort peptides are hypothesized to modify chromatin structure in adrenal cortex cells, potentially reactivating genes silenced by age-related heterochromatin condensation. This mechanism, while plausible given the demonstrated effects of related peptides, has not been experimentally confirmed for adrenal-specific peptides.

3. Researched Applications

Chronic Adrenal Cortex Insufficiency

Evidence level: Single open-label clinical study

The primary clinical study of Glandokort was conducted at the Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology from April to November 2011. It enrolled 36 patients aged 37 to 62 years with two categories of conditions:

1. Chronic adrenal cortex insufficiency of various etiologies
2. Post-stress adrenal dysfunction after prolonged exposure to occupational and psycho-emotional stress

Patients received Glandokort at 1 capsule, 2 times daily with meals for 30 days. The study employed radioimmunological methods to measure cortisol and insulin in blood serum, and biochemical methods to determine adrenaline and aldosterone in blood plasma.

Results: Glandokort demonstrated [4]:

• Restoration of metabolic activity in the reticular adrenal zone
• Increased production of aldosterone (mineralocorticoid)
• Increased production of 17-ketosteroids (androgenic markers)
• Normalization of cortisol levels in blood serum
• Normalization of insulin levels
• No adverse effects reported in any patient

These results suggest that Glandokort can restore both mineralocorticoid (aldosterone) and androgenic (17-ketosteroid) function of the adrenal cortex, which are the functions most commonly compromised in chronic adrenal insufficiency and chronic stress states.

Occupational and Psycho-Emotional Stress Recovery

Evidence level: Included in clinical study cohort

A subset of the clinical study patients had adrenal dysfunction attributable to prolonged occupational stress and psycho-emotional stress rather than primary adrenal disease. The improvement in adrenal function in this subgroup supports the use of Glandokort for stress-related adrenal fatigue, although the concept of "adrenal fatigue" remains controversial in mainstream endocrinology.

Age-Related Endocrine Decline

Evidence level: Theoretical/framework-based

Within the Khavinson bioregulator system, Glandokort is indicated for age-related decline in adrenal function, which manifests as reduced DHEA and cortisol production, decreased stress resilience, and metabolic changes [1]. The rationale is consistent with the well-documented age-related decline in adrenal androgen production (adrenopause), though no controlled studies of Glandokort specifically for age-related adrenal decline have been published.

Post-Disease Endocrine Recovery

Evidence level: Clinical observation

Glandokort is marketed for restoration of endocrine function after diseases of various origins, exposure to extreme environmental factors, and malnutrition [4]. These indications are broad and based on the general bioregulator framework rather than specific clinical trials.

4. Clinical Evidence Summary

5. Dosing in Research

Standard Protocol

The manufacturer recommends 1-2 capsules, 1-2 times daily with meals for 30 days. The clinical study used the lower end of this range (1 capsule twice daily). Courses are typically repeated every 3-6 months.

Morning Administration

Given that cortisol follows a diurnal rhythm with peak levels in the morning, some practitioners suggest morning administration of Glandokort to align with the natural cortisol curve. This timing recommendation has not been validated in controlled studies.

Combination Protocols

In the Khavinson bioregulator system, Glandokort is sometimes combined with:

• Endoluten (pineal peptides) for neuroendocrine axis support
• Thyreogen (thyroid peptides) for broader endocrine optimization
• Ventfort (vascular peptides) to support adrenal blood supply

No controlled studies have evaluated these combinations.

6. Safety and Side Effects

Published Safety Data

No adverse effects were reported in the clinical study of 36 patients receiving Glandokort for 30 days [4]. This finding is consistent with the broader Khavinson bioregulator safety profile, which reports no toxic, allergic, or adverse effects across the entire history of clinical application [4][5].

Hormonal Safety Considerations

A critical question for any adrenal-targeting preparation is whether it could cause hormonal excess or suppress endogenous production through negative feedback. The bioregulator theory proposes that peptide bioregulators normalize rather than overstimulate hormonal output, but this claim has not been rigorously tested with dose-response studies or hormonal monitoring over extended use periods.

Specific concerns include:

• Cortisol modulation: Could Glandokort increase cortisol production in patients who already have adequate or elevated levels? The normalizing claim implies not, but evidence is absent.
• Aldosterone effects: Increased aldosterone could theoretically contribute to sodium retention, hypertension, and potassium depletion in susceptible individuals
• Androgenic effects: Increased 17-ketosteroid production could theoretically affect sex hormone balance

Critical Safety Gaps

• No formal endocrine safety studies with serial hormone monitoring
• No pharmacokinetic data -- oral bioavailability and systemic peptide levels undefined
• No drug interaction studies -- effects when combined with corticosteroids, mineralocorticoid receptor antagonists, or other endocrine medications are unknown
• No safety data in patients with adrenal adenomas, Cushing's syndrome, primary aldosteronism, or other conditions where hormonal stimulation could be harmful
• No independent safety monitoring outside Khavinson's institution
• As a biological extract, potential concerns regarding batch variability and contaminants apply

Contraindications

Manufacturer-listed contraindications include individual intolerance to any component, pregnancy, and breastfeeding. Given the endocrine-active nature of the preparation, caution would be prudent in patients with known adrenal tumors, hyperaldosteronism, Cushing's syndrome, or other conditions of adrenal hormone excess.

7. The AEDLA Sequence Question

Some commercial and reference sources associate Glandokort with the pentapeptide sequence AEDLA (Ala-Glu-Asp-Leu-Ala). This association requires careful qualification:

• Unlike Epithalon (AEDG) and Cortagen (AEDP), which have documented derivation histories described in peer-reviewed publications, the AEDLA sequence's connection to Glandokort lacks equivalent published documentation
• No PubMed-indexed studies specifically investigating the AEDLA pentapeptide were found
• No microarray, chromatin remodeling, or receptor binding studies specific to AEDLA have been published
• The sequence may originate from amino acid analysis of the adrenal extract, similar to how AEDG and AEDP were derived from their respective tissue extracts, but the published evidence for this derivation is absent

Until peer-reviewed research specifically investigating the AEDLA sequence is published, the connection between this defined sequence and Glandokort's biological activity should be treated as unverified. Glandokort's observed clinical effects may derive from multiple peptide components within the crude extract rather than from a single defined sequence.

7. Comparison with Related Approaches

Glandokort vs. Conventional Adrenal Support

| Approach | Glandokort | Hydrocortisone Replacement | Adaptogenic Herbs | |----------|------------|---------------------------|-------------------| | Mechanism | Peptide-mediated gene regulation | Direct hormone replacement | Stress axis modulation | | Evidence level | Single open-label study | Extensive RCT evidence | Variable (some RCTs) | | Regulatory status | Dietary supplement (Russia) | Prescription medicine (global) | Dietary supplement (global) | | Risk of suppression | Claimed to be normalizing | Can suppress HPA axis | Generally not suppressive | | Specificity | Adrenal cortex-targeted | Direct cortisol/aldosterone provision | Nonspecific stress adaptation |

Glandokort vs. Other Khavinson Endocrine Bioregulators

The Khavinson system includes several endocrine-targeting bioregulators:

• Endoluten (A-8): Pineal gland -- melatonin and circadian rhythm regulation
• Thyreogen (A-6): Thyroid gland -- T3/T4 production support
• Zhenoluten (A-9): Ovaries -- female reproductive hormone support
• Testoluten (A-10): Testes -- testosterone and male reproductive support
• Suprefort (A-11): Pancreas -- insulin and digestive enzyme regulation

Glandokort addresses the adrenal component of this endocrine system, and is sometimes used in combination with these other preparations for comprehensive endocrine support.

9. Pharmacokinetics

No pharmacokinetic studies have been published for Glandokort. As a polypeptide complex containing peptides up to 5,000 Da administered orally, it faces the same fundamental bioavailability challenges as other Khavinson Cytomax preparations.

Oral peptide bioavailability is generally very low. The smaller peptide fractions within Glandokort may be transported via PepT1 transporters in the intestinal epithelium, but larger fractions would require degradation before absorption. No studies have measured intact Glandokort peptide components in plasma or adrenal tissue following oral administration.

The proposed target tissue (adrenal cortex) is a well-vascularized endocrine organ with high blood flow, which theoretically facilitates delivery of systemically absorbed peptides. However, the adrenal cortex is also protected by the adrenal capsule, and whether small peptide fragments can penetrate to reach steroidogenic cells at biologically active concentrations is unknown.

The clinical study demonstrated hormonal changes (increased aldosterone and 17-ketosteroids, normalized cortisol and insulin) following 30 days of oral administration [4], suggesting that some biologically active component reaches target tissues via the oral route. However, these hormonal changes could also reflect indirect effects mediated by gut-peptide signaling, immune modulation, or other pathways not requiring intact peptide delivery to adrenal cells.

10. Dose-Response

No dose-response studies have been conducted for Glandokort. The clinical study used a single protocol (1 capsule twice daily for 30 days) without dose comparison [4]. The manufacturer's recommended range (1-2 capsules, 1-2 times daily) represents a 4-fold dose range without guidance on optimal dosing.

The absence of dose-response data is particularly problematic for an endocrine-active preparation. The claimed "normalizing" property of Glandokort -- increasing deficient hormone production without stimulating excess production -- implies a nonlinear dose-response curve with a self-limiting plateau. This is pharmacologically unusual and has not been demonstrated through titration studies. Most endocrine-active agents show dose-proportional effects that can produce both therapeutic and supratherapeutic hormone levels.

No studies have examined the relationship between Glandokort dose and specific hormonal endpoints (cortisol, aldosterone, DHEA, 17-ketosteroids) across multiple dose levels in the same patient population.

11. Comparative Effectiveness

Glandokort vs. Hydrocortisone Replacement

Hydrocortisone replacement therapy is the standard of care for adrenal insufficiency, with decades of clinical evidence, well-defined dosing (15-25 mg/day in divided doses), and established pharmacokinetics. It provides direct cortisol replacement via a known receptor (glucocorticoid receptor). Glandokort proposes to restore endogenous cortisol production rather than replace it, which is a fundamentally different approach. No comparative data exist.

Glandokort vs. Adaptogens

Adaptogenic herbs (ashwagandha, rhodiola, eleuthero) are widely used for stress-related adrenal support. Some have RCT evidence for cortisol modulation and stress resilience. Adaptogens act through nonspecific stress response modulation (AMPK, Nrf2, heat shock proteins), while Glandokort proposes tissue-specific gene regulation. No comparative studies exist between Glandokort and any adaptogen.

Glandokort vs. DHEA Supplementation

Oral DHEA is a widely available supplement used for age-related adrenal androgen decline (adrenopause). It has multiple RCTs showing modest effects on body composition, bone density, and quality of life in elderly populations. Glandokort claims to restore endogenous 17-ketosteroid production rather than providing exogenous DHEA. The evidence base for DHEA vastly exceeds that for Glandokort.

12. Enhanced Safety

No adverse effects were reported in the 36-patient clinical study [4]. The broader Khavinson safety profile across all bioregulators reports no toxic, allergic, or adverse effects [4][5].

The endocrine-active nature of Glandokort requires more stringent safety consideration than peptides targeting non-endocrine tissues. Specific concerns include:

Cortisol modulation risk: In patients with already adequate or elevated cortisol (e.g., chronic stress, metabolic syndrome), stimulation of cortisol production could worsen hypertension, insulin resistance, osteoporosis, or immunosuppression. The "normalizing" claim has not been validated with serial cortisol monitoring across diverse patient populations.

Aldosterone effects: Increased aldosterone production could theoretically cause sodium retention, potassium depletion, and blood pressure elevation in susceptible individuals. No monitoring for these electrolyte effects was reported in the clinical study.

Contraindicated conditions: Patients with adrenal adenomas, Cushing's syndrome, primary aldosteronism, congenital adrenal hyperplasia, or adrenal carcinoma could theoretically be harmed by an agent that stimulates adrenal function. No safety data in any of these populations exist.

No drug interaction studies have been conducted. Potential interactions with exogenous corticosteroids, mineralocorticoid receptor antagonists (spironolactone, eplerenone), DHEA supplements, or other endocrine medications are unknown.

13. Related Peptides

See also: Endoluten, Thymalin, Epithalon, Cerluten

14. References

1. [1] Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters. PubMed
2. [2] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
3. [3] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
4. [4] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Message 2: Clinical studies results. Advances in Gerontology. PubMed
5. [5] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Message 1: Results of experimental studies. Advances in Gerontology. DOI
6. [6] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
7. [7] Khavinson VKh, Lezhava TA, Malinin VV. (2003). Effects of short peptides on lymphocyte chromatin in aged people. Bulletin of the Georgian National Academy of Sciences.
8. [8] Khavinson VKh, Kuznik BI, Ryzhak GA. (2012). Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. DOI PubMed
9. [9] Linkova NS, Khavinson VKh. (2019). Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b. Molecular Biology. DOI
10. [10] Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. (2005). Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. DOI PubMed
11. [11] Goncharova ND, Khavinson VKh, Vengerin AA, Lapin BA. (2001). Regulatory effect of epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine. DOI PubMed
12. [12] Ilina A, Khavinson V, Linkova N, Petukhov M. (2025). Overview of Epitalon -- Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. DOI PubMed
13. [13] Khavinson VKh, Linkova NS, Dyatlova AS, Kantemirova RK, Kozlov KL. (2021). EDR Peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules. DOI PubMed
14. [14] Khavinson VKh, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Ori T, Sinjari B. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. DOI PubMed
15. [15] Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. DOI PubMed